Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Antimicrobial peptide therapeutics for cystic fibrosis.

Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ.

Antimicrob Agents Chemother. 2005 Jul;49(7):2921-7.

2.

Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection.

Song Z, Wu H, Mygind P, Raventos D, Sonksen C, Kristensen HH, Høiby N.

Antimicrob Agents Chemother. 2005 Sep;49(9):3868-74.

3.

Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed α-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia.

Pompilio A, Crocetta V, Scocchi M, Pomponio S, Di Vincenzo V, Mardirossian M, Gherardi G, Fiscarelli E, Dicuonzo G, Gennaro R, Di Bonaventura G.

BMC Microbiol. 2012 Jul 23;12:145. doi: 10.1186/1471-2180-12-145.

4.

Highly selective end-tagged antimicrobial peptides derived from PRELP.

Malmsten M, Kasetty G, Pasupuleti M, Alenfall J, Schmidtchen A.

PLoS One. 2011 Jan 27;6(1):e16400. doi: 10.1371/journal.pone.0016400.

5.

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.

Conway SP, Brownlee KG, Denton M, Peckham DG.

Am J Respir Med. 2003;2(4):321-32. Review.

PMID:
14719998
6.

In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens.

Schwab U, Gilligan P, Jaynes J, Henke D.

Antimicrob Agents Chemother. 1999 Jun;43(6):1435-40.

7.

Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients.

Pompilio A, Scocchi M, Pomponio S, Guida F, Di Primio A, Fiscarelli E, Gennaro R, Di Bonaventura G.

Peptides. 2011 Sep;32(9):1807-14. doi: 10.1016/j.peptides.2011.08.002. Epub 2011 Aug 7.

PMID:
21849157
8.

Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.

Saiman L, Tabibi S, Starner TD, San Gabriel P, Winokur PL, Jia HP, McCray PB Jr, Tack BF.

Antimicrob Agents Chemother. 2001 Oct;45(10):2838-44.

9.

Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.

Aichele D, Schnare M, Saake M, Röllinghoff M, Gessner A.

Infect Immun. 2006 Aug;74(8):4708-14.

11.

Effects of Chinese medicinal herbs on a rat model of chronic Pseudomonas aeruginosa lung infection.

Song Z, Johansen HK, Moser C, Høiby N.

APMIS. 1996 May;104(5):350-4.

PMID:
8703440
12.

Antimicrobial peptides containing unnatural amino acid exhibit potent bactericidal activity against ESKAPE pathogens.

Hicks RP, Abercrombie JJ, Wong RK, Leung KP.

Bioorg Med Chem. 2013 Jan 1;21(1):205-14. doi: 10.1016/j.bmc.2012.10.039. Epub 2012 Nov 1.

PMID:
23199484
14.

Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens.

Benincasa M, Mattiuzzo M, Herasimenka Y, Cescutti P, Rizzo R, Gennaro R.

J Pept Sci. 2009 Sep;15(9):595-600. doi: 10.1002/psc.1142.

PMID:
19466693
15.

In vitro and in vivo activities of antimicrobial peptides developed using an amino acid-based activity prediction method.

Wu X, Wang Z, Li X, Fan Y, He G, Wan Y, Yu C, Tang J, Li M, Zhang X, Zhang H, Xiang R, Pan Y, Liu Y, Lu L, Yang L.

Antimicrob Agents Chemother. 2014 Sep;58(9):5342-9. doi: 10.1128/AAC.02823-14. Epub 2014 Jun 30.

16.

Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Chmiel JF, Aksamit TR, Chotirmall SH, Dasenbrook EC, Elborn JS, LiPuma JJ, Ranganathan SC, Waters VJ, Ratjen FA.

Ann Am Thorac Soc. 2014 Sep;11(7):1120-9. doi: 10.1513/AnnalsATS.201402-050AS. Review.

17.

Mouse models of chronic lung infection with Pseudomonas aeruginosa: models for the study of cystic fibrosis.

Stotland PK, Radzioch D, Stevenson MM.

Pediatr Pulmonol. 2000 Nov;30(5):413-24. Review.

PMID:
11064433
18.
19.

Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.

Hogardt M, Schmoldt S, Götzfried M, Adler K, Heesemann J.

J Antimicrob Chemother. 2004 Dec;54(6):1057-61. Epub 2004 Oct 27.

PMID:
15509615
20.

P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients.

Sajjan US, Tran LT, Sole N, Rovaldi C, Akiyama A, Friden PM, Forstner JF, Rothstein DM.

Antimicrob Agents Chemother. 2001 Dec;45(12):3437-44.

Supplemental Content

Support Center